471TiP RASolute 303: A phase III global, multicenter, open-label, randomized 3-arm study of daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel as a first line treatment for patients with metastatic pancreatic adenocarcinoma
作者
Thomas Theodor Werner Seufferlein,Pascal R. Hammel,Filippo Pietrantonio,N.S. Azad,A.H. Ko,Chigusa Morizane,S.L. Chan,W. Novotny,Y. Xu,J. Liu,S. Pant